John Sfakianos is a Genitourinary physician affiliated with Mount Sinai Hospital. OpenAlex indexes 497 publications with 9,208 citations (h-index 45); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Urology profiles in the FindMyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
Sponsor: Icahn School of Medicine at Mount Sinai
- A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Sponsor: John Sfakianos
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JanssenProgram year20253 paymentsResearch$81,156openpaymentsdata.cms.gov ↗
- UROGEN PHARMA, INC.Program year202538 payments$53,766openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202514 payments$19,824openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
NIH funding
3 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis
Icahn School of Medicine at Mount Sinai
FY2026$683,333R01CA301050 - HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer
Icahn School of Medicine at Mount Sinai
FY2026$667,174R01CA269954 - Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis
Icahn School of Medicine at Mount Sinai
FY2025$684,877R01CA301050
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel J. Drucker
Mount Sinai Hospital
Karyn Goodman, MD
Mount Sinai Hospital
Edward Wolin, MD
Mount Sinai Hospital
Richard Bakst, MD
Mount Sinai Hospital
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”